<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555408</url>
  </required_header>
  <id_info>
    <org_study_id>2019ZSQN44</org_study_id>
    <nct_id>NCT04555408</nct_id>
  </id_info>
  <brief_title>Efficacy of Blue Light Treatment in Patients With Nonseasonal Major Depressive Disorder</brief_title>
  <official_title>Efficacy of Blue Light Treatment in Patients With Nonseasonal Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Mental Health Center, Jingan District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center, Yangpu District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of blue light, bright light and dim light in the treatment of with&#xD;
      nonseasonal major depression disorder(MDD) in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study aims to compare the efficacy of blue light, bright light and dim light in&#xD;
      the treatment of with nonseasonal major depression disorder(MDD) in adults. 162 patients with&#xD;
      nonseasonal MDD will be randomized into three groups (i.e. blue light, bright light or dim&#xD;
      light). The treatment will be performed five times a week for the first two weeks. And for&#xD;
      the next 2 weeks, the treatment for patients will be undertook three times a week. There will&#xD;
      be 16 times in total. The investigators will assess nonseasonal MDD'symptom severity in the&#xD;
      baseline, 1 week,2 week, 4 week,6 week and 8 week. Through the study, 17-item Hamilton&#xD;
      Depression Rating Scale (HAMD17),14-item Hamilton Anxiety Rating Scale (HAMA14),Quick&#xD;
      Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR)，Pittsburgh sleep quality index&#xD;
      (PSQI) , Clinical Global Impression scale(CGI), Quality of Life, Enjoyment and Satisfaction&#xD;
      Questionnaire (Q-LES-Q),Morningness-Eveningness Questionnaire (MEQ),Repeatable Battery for&#xD;
      the Assessment of Neuropsychological Status(RBANS),subjective fatigue symptom scale and&#xD;
      semantic differential scale will be obtained. The patients will also get individual's data of&#xD;
      heart rate and blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 17-item Hamilton Depression Rating Scale (HAMD17)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses the severity of depression symptom. The responder on HAMD17 is defined as a HAMD17 decrease at least 50% from the baseline at post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quick Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It's a self-rated inventory which assesses the severity of depression symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 14-item Hamilton Anxiety Rating Scale (HAMA14)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses the severity of anxiety symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pittsburgh sleep quality index (PSQI)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses the quality of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression scale(CGI)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It gives an overall clinical impression to the continuous outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses the quality of life, enjoyment and satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morningness-Eveningness Questionnaire (MEQ)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses the circadian phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Repeatable Battery for the Assessment of Neuropsychological Status(RBANS)</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective fatigue symptom scale</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses subjective fatigue symptom related to the light therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in semantic differential scale</measure>
    <time_frame>from baseline to 8 weeks</time_frame>
    <description>It assesses subjective feeling related to the light therapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>blue light group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bright light group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dim light group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>blue light</intervention_name>
    <description>Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.</description>
    <arm_group_label>blue light group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bright light</intervention_name>
    <description>Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.</description>
    <arm_group_label>bright light group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dim light</intervention_name>
    <description>Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.</description>
    <arm_group_label>dim light group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  meet criteria for major depressive episodes as determined by MINI&#xD;
&#xD;
          -  HAMD17≥17&#xD;
&#xD;
          -  received antidepressive medication at stable dosages for at least 14 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any axis I psychiatric disorder comorbidity&#xD;
&#xD;
          -  who have received formal psychological therapy, MECT or rTMS in 3 months&#xD;
&#xD;
          -  any current significant medical condition especially eye diseases&#xD;
&#xD;
          -  serious suicide risk&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  depression with seasonal pattern&#xD;
&#xD;
          -  treatment-resistant depression&#xD;
&#xD;
          -  epilepsy in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Wang, MD</last_name>
    <phone>64041990</phone>
    <email>wang.yuan@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Huang, MD,PhD</last_name>
    <phone>64041990</phone>
    <email>slehuang@163.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nonseasonal major depression disorder</keyword>
  <keyword>light therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

